Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AGN will acquire Esprit for $370 million in cash. Esprit markets Sanctura trospium to treat overactive bladder (OAB) and Estrasorb topical 17beta estradiol
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury